Gastric CancersNCT06686966
Prediction of Postoperative Complications and Survival in Gastric Cancer Using Preoperative Blood Markers
An observational study of Gastric Cancers, run by First Affiliated Hospital of Chongqing Medical University.
Trial summary
Gastric cancer is one of the most common cancers worldwide, especially in East Asia. Although surgery remains the main treatment, patients may experience postoperative complications and have varying long-term survival outcomes. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Gastric Cancers
- What is being tested?
- gastric cancer
- How many people
- 3,400 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2010to 1 Nov 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients diagnosed with gastric cancer and undergoing radical gastric cancer surgery at the First Hospital of Chongqing Medical University, the Second Hospital of Chongqing Medical University, and the Yongchuan Hospital of Chongqing Medical University.
Who may be able to join
- patients aged ≥18 years;
- patients diagnosed with gastric cancer by pathological biopsy before surgery;
- patients without chemotherapy, radiotherapy, targeted and immunotherapy before enrolment;
- willing to participate in this study and sign the informed consent;
- complete clinical data.
Who cannot join
- patients with other primary malignant tumours other than gastric cancer;
- patients with systemic diseases such as severe cardiopulmonary insufficiency that affect the choice of treatment plan;
- patients who are not suitable for enrolment as assessed by the investigator;
- incomplete clinical data.
About this study
Official title: Clinical Study on the Effect of Preoperative Serum Biomarkers on the Prognosis of Gastric Cancer
Gastric cancer is one of the most common cancers worldwide, especially in East Asia. Although surgery remains the main treatment, patients may experience postoperative complications and have varying long-term survival outcomes. Early identification of high-risk patients before surgery is important for improving treatment decisions and patient management.
This study aims to develop a prediction model based on routinely available preoperative blood test results and clinical characteristics to estimate the risk of postoperative complications and long-term survival in patients with gastric cancer. The model will be developed and validated using data from multiple medical centers.
By using easily accessible clinical information, this study seeks to provide a practical tool to help clinicians better assess patient risk before surgery, support personalized treatment planning, and improve overall patient outcomes.
- Conditions
- Gastric Cancers
- Being tested
- gastric cancer
- Keywords
- gastric cancer, machine learning, serum biomarkers
- Medical subject headings
- Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
gastric cancerDiagnostic test
be diagnosed as gastric cancer
What is being measured
The primary outcome is the main question the study is designed to answer.
the incidence of gastric cancer
the diagnosis time of gastric cancer
Measured: From 18 years old until the developing gastric cancer, through study completion, an average of 5 year.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Nov 2024
- Study start1 Jan 2010
- Primary completion1 Nov 2024
- Study completion1 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric CancersStudies of the same condition, open and under way.
- More trials run by First Affiliated Hospital of Chongqing Medical UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 3,400 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dong Peng, First Affiliated Hospital of Chongqing Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06686966
- Sponsor's protocol ID
- ZZ2024-292-01
- Status last verified
- Feb 2026
- First submitted
- 12 Nov 2024
- Last updated
- 3 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: None of the three clinical centres conducting the study allowed the disclosure of patient information and data sharing.
Study at a glance
From the registry record, last updated by the sponsor on 3 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Study on the Effect of Preoperative Serum Biomarkers on the Prognosis of Gastric Cancer
- ClinicalTrials.gov ID
- NCT06686966
- Acronym / sponsor ID
- ZZ2024-292-01
- Conditions
- Gastric Cancers
- Keywords
- gastric cancer, machine learning, serum biomarkers
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,400 participants (actual)
- Lead sponsor
- First Affiliated Hospital of Chongqing Medical UniversityUniversity, hospital or other
- Study start
- 1 Jan 2010 (actual)
- Primary completion
- 1 Nov 2024 (actual)
- Study completion
- 1 Nov 2024 (actual)
- First posted
- 13 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Gastric cancer is one of the most common cancers worldwide, especially in East Asia. Although surgery remains the main treatment, patients may experience postoperative complications and have varying long-term survival outcomes. Early identification of high-risk patients before surgery is important for improving treatment decisions and patient management.
This study aims to develop a prediction model based on routinely available preoperative blood test results and clinical characteristics to estimate the risk of postoperative complications and long-term survival in patients with gastric cancer. The model will be developed and validated using data from multiple medical centers.
By using easily accessible clinical information, this study seeks to provide a practical tool to help clinicians better assess patient risk before surgery, support personalized treatment planning, and improve overall patient outcomes.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with gastric cancer and undergoing radical gastric cancer surgery at the First Hospital of Chongqing Medical University, the Second Hospital of Chongqing Medical University, and the Yongchuan Hospital of Chongqing Medical University.
Key inclusion criteria (5 listed)
- patients aged ≥18 years;
- patients diagnosed with gastric cancer by pathological biopsy before surgery;
- patients without chemotherapy, radiotherapy, targeted and immunotherapy before enrolment;
- willing to participate in this study and sign the informed consent;
- complete clinical data.
Key exclusion criteria (4 listed)
- patients with other primary malignant tumours other than gastric cancer;
- patients with systemic diseases such as severe cardiopulmonary insufficiency that affect the choice of treatment plan;
- patients who are not suitable for enrolment as assessed by the investigator;
- incomplete clinical data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| gastric cancerbe diagnosed as gastric cancer | Diagnostic test | – |
Primary outcome
the incidence of gastric cancer
Time frame: From 18 years old until the developing gastric cancer, through study completion, an average of 5 year.
the diagnosis time of gastric cancer
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Mar 2026.
- Individual participant dataSharing planned: No. None of the three clinical centres conducting the study allowed the disclosure of patient information and data sharing.
Related trials for Gastric Cancers
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
RecruitingPhase 3
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Gastric, Esophagogastric Junction
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastric Cancers, run by First Affiliated Hospital of Chongqing Medical University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the incidence of gastric cancer (time frame: From 18 years old until the developing gastric cancer, through study completion, an average of 5 year.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2026.